Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
arcticnovartis
Mon, 08/11/2025 – 07:19
Read more about Novartis announces both ianalumab Phase III clinical trials met …
